Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;13(9):525-537.
doi: 10.1038/nrrheum.2017.107. Epub 2017 Jul 13.

Antigen-specific immunotherapies in rheumatic diseases

Judit Pozsgay  1 , Zoltán Szekanecz  2 , Gabriella Sármay  1
Affiliations
Review

Antigen-specific immunotherapies in rheumatic diseases

Judit Pozsgay et al. Nat Rev Rheumatol. 2017 Sep.

Abstract

The main goal of antigen-specific immunotherapy (ASI) in autoimmune and rheumatic diseases is to reprogramme or remove autoreactive cells and/or induce immune tolerance to self-antigens. Current therapies in these diseases either treat symptoms or slow down disease progression but are not yet curative or preventative - disease-specific treatments are urgently needed. In contrast to the nonspecific treatments in current use that induce generalized immune suppression, which is associated with several adverse effects including increased risk of infections, ASIs target a restricted subset of B cells or T cells, and thus do not compromise systemic immunity and host defence. This Review provides a summary of novel approaches for identifying autoepitopes and detecting and targeting autoreactive cells that might help in the development of ASIs. Promising approaches include the use of tolerizing peptides coupled to MHC constructs and/or nanocompounds, tolerizing dendritic cells and antigen-specific vaccines. Following studies in animal models of rheumatoid arthritis and systemic lupus erythematosus, several of these strategies have now entered clinical trials. However, to use these approaches in humans, several important limitations must first be addressed, such as; selecting the proper immunodominant autoantigen; identifying the optimal timing, dosing and route of administration; finding biomarkers for monitoring the therapy; and optimizing methodology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Hepatol. 2015 Jun;62(6):1349-56 - PubMed
    1. Nat Rev Immunol. 2012 Sep;12 (9):669-77 - PubMed
    1. Scand J Clin Lab Invest Suppl. 2001;235:16-26 - PubMed
    1. Ann Rheum Dis. 2010 Sep;69(9):1580-8 - PubMed
    1. J Immunol. 2005 Mar 15;174(6):3247-55 - PubMed